AstraZeneca, US6549022043

AstraZeneca stock gains on analyst support and July results

Published on 09/07/2026 at 15:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock is trading near the USD 162 level as analysts keep a buy stance and the company's July 27 quarter showed USD 15.38 billion in revenue and USD 2.63 EPS.

Fotorealistisches Pharmaforschungslabor mit Wissenschaftlern in weißen Kitteln an Mikroskopen und Analysegeräten bei hellem klinischen Licht — AstraZeneca US6549022043 zeigt modernes Pharma Forschungslabor mit Wissenschaftlern an Mikroskopen und Analysegeräten, Illustration mit AI erstellt.

AstraZeneca stock (US6549022043) is trading around USD 162.62, while MarketBeat says the company has a market cap of USD 252.21 billion and a consensus target price of USD 206.67 as of September 7, 2026. The last reported quarter, on July 27, 2026, delivered revenue of USD 15.38 billion and EPS of USD 2.63.

Analysts still see upside

Jefferies kept its buy view on the stock and left its target at 17,500 GBX, while JP Morgan also maintained an overweight stance and a 16,000 GBX target. The average target from the same analyst snapshot stands at USD 212.94, compared with a last close of USD 162.34 in the cited London-linked overview.

The comparison is clear: the July 27 quarter brought USD 15.38 billion in revenue, up 6.4 percent year on year, and EPS of USD 2.63, above the USD 2.50 consensus by USD 0.13. Net margin reached 17.02 percent, which gives the recent numbers more weight than the headline rating activity alone.

July quarter sets the tone

MarketBeat's July 27 earnings summary also says AstraZeneca had a return on equity of 31.45 percent. That combination of 6.4 percent revenue growth and a 17.02 percent net margin is the key operating backdrop for the stock into early September.

Product and pipeline

The company's oncology and specialty medicines franchise remains the main product engine behind the numbers, with the July 27 quarter showing that the business still converts revenue into earnings at a high margin. For investors, the current debate is less about the business model and more about whether that growth profile can keep matching a consensus target above USD 206.

Price near 52-week context

AstraZeneca stock last opened at USD 162.62 and traded at USD 162.62 in the cited snapshot, with a 50-day moving average of USD 169.21 and a 200-day moving average of USD 183.86. The same source put the share's market cap at USD 252.21 billion on September 7, 2026.